LRMR · Larimar Therapeutics, Inc.
$3.93
+0.10 (+2.61%)
At close · Jul 21
Market Cap
$408.26M
Shares
103.88M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $3,526,423 |
| Michael Celano | CFO | $1,697,960 |
| Gopi Shankar | Chief Development Officer | $1,293,329 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $2,511,649 |
| Michael Celano | CFO | $1,384,705 |
| Gopi Shankar | Chief Development Officer | $1,165,126 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $3,137,431 |
| Michael Celano | CFO | $1,418,152 |
| Gopi Shankar | Chief Development Officer | $1,381,721 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $2,129,549 |
| Michael Celano | CFO | $1,132,323 |
| Gopi Shankar | Chief Development Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $2,233,823 |
| Michael Celano | CFO | $1,065,755 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Carole S. Ben-Maimon | CEO | $5,270,178 |
| Michael Celano | CFO | $1,790,739 |
| Jeffrey S. Hatfield | CEO | $1,351,638 |
| Patricia Allen | CFO | $1,130,979 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jeffrey S. Hatfield | CEO | $3,236,560 |
| Priya Singhal | Former Head of Research & Development | $1,398,665 |
| Brian P. McVeigh | Former Chief Business Officer | $1,091,509 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Jeffrey S. Hatfield | CEO | $2,468,855 |
| Brian P. McVeigh | Former Chief Business Officer | $1,462,930 |